Dechu Puliyanda, MD
Pediatric Nephrology · West Hollywood, CANPI 1114955705
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,413 of the $21,063 with a category attached, or 73.2%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 65.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $13,921 and has fallen 97.6% since, to $334 in 2025. Among pediatric nephrology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $679.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Kaneka Medical America LLC$7K
- Sanofi$150
- Travere Therapeutics, Inc.$92
- Novartis$90
- Apellis Pharmaceuticals, Inc.$86
- plus $137 from 5 others
Across 7 payments — averaging $5215.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$37K
What the payments were for
- Consulting fees$3,10615%
- Speaking & faculty fees$15,41373%
- Travel & lodging$1,3636%
- Food & beverage$1,1826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $13,850 |
| Kaneka Medical America LLC | 3 | $6,657 |
| Sanofi | 1 | $150 |
| Travere Therapeutics, Inc. | 2 | $92 |
| Novartis | 3 | $90 |
| Apellis Pharmaceuticals, Inc. | 3 | $86 |
| Silvergate Pharmaceuticals, Inc. | 2 | $33 |
| Amgen | 1 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIVTENCITY$13,619
- THYMOGLOBULIN$150
How this compares
$21,063 in reported general payments places this provider in the 90th percentile of 75 pediatric nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin | 13 | $18,722 |
| Mycophenolate Mofetil | 11 | $6,470 |
| Famotidine | 11 | $2,511 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in West Hollywood
- Helen PizzoWest Hollywood$440
- Paul GrimmPalo Alto$99K
- Isidro SaluskyLos Angeles$47K
- Ora YadinLos Angeles$42K
- Shina MenonPalo Alto$28K
- Elaine KamilLos Angeles$18K
- Sophia GiangPalo Alto$15K
- Patricia WengLos Angeles$8K
- Rachana SrivastavaLos Angeles$7K
- Ruby PatelPalo Alto$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.